Abstract. Leucine-rich repeat-containing G-protein coupled receptor 5 (Lgr5) is well-characterized as a marker of intestinal stem cells and certain types of tumor stem cells, where positive cells may develop into intestinal epithelial cells or intestinal adenomas. However, the roles of Lgr5 in the lung and in lung tumors remain unclear. An immunohistochemistry (IHC) analysis was performed to detect the expression of Lgr5 in the lung from a normal mouse. Histopathological sections of the lungs from Lgr5 heterozygous knockout mice (Lgr5 +/-) were observed following with hematoxylin and eosin. Furthermore, tissue microarrays containing tumor cores from lung cancer patients were also analyzed by IHC. Lgr5-positive cells were present in the pulmonary alveoli and bronchi of normal mice, whereas the lungs of Lgr5 +/-mice lost their normal morphological structure compared with the lungs of the normal mice. Lgr5 was expressed in lung adenocarcinoma, however, not in squamous carcinoma, and Lgr5 expression was positively associated with tumor, node, metastasis stage. Lgr5 is expressed in normal murine lung and is associated with TNM stage in patients with lung adenocarcinoma.
Introduction
In 1998, Hsu et al (1) found that the leucine-rich repeat-containing G-protein coupled receptor 5 (Lgr5) was homologous to the gonadotropin and thyrotropin receptors in Drosophila (1) . Lgr5 is expressed in the eye, brain, mammary glands, hair follicles, stomach, intestines and other tissues (2, 3) . Lgr5 serves an important role in the Wnt signaling pathway, which is intimately involved in tumor development (4) (5) (6) . Lgr5 is a marker of stem cells in the intestine, mammary glands and hair follicles. Lgr5 is also expressed in intestinal tumors (7, 8) , which are composed of crypt base columnar cells and stem cells. In addition, Lgr5 is expressed in hepatocellular carcinoma, breast cancer and gastric carcinoma. However, its role in normal lung and in lung cancer remains unknown.
Lung cancer is the leading cause of cancer-assocaited mortality among males in developed countries (9) . Few studies reporting on Lgr5 in lung cancer have been published in recent years (10, 11) . To investigate whether Lgr5 serves a role in lung cancer similar to that in colorectal cancer and to determine whether Lgr5 functions in the maintenance of lung structure, the present study assessed the structure of the lungs in Lgr5 heterozygous knockout mice (Lgr5 +/-). Notbaly, it was demonstrated that the lungs of Lgr5 +/-mice were abnormal compared with those of wild-type (WT) mice, which suggested that Lgr5 functions in the maintenance of normal lung structure. Furthermore, Lgr5 expression was analyzed in tumor tissues of patients with lung cancer. The present study indicated that Lgr5 serves an important role in lung adenocarcinoma and provided some meaningful insight into the presence of Lgr5-positive cells in the lungs and Lgr5 expression in lung cancer.
Materials and methods
Mice. Genetically engineered mice [B6.129P2-Lgr5tm1 (cre/ERT2) Cle/J] were donated to our laboratory by Professor Geng (Department of Biologic and Materials Sciences, University of Michigan School of Dentistry, Ann Arbor, MI, USA). This mouse model was produced by knock-in of the Lgr5-EGFP-IRES-creERT2 allele, which results in the loss of function of one Lgr5 allele and the expression of the CreERT2-EGFP fusion protein. Lgr5 mice do not exhibit any obvious abnormalities in terms of birth rate or any abnormal physiological properties. By contrast, the homozygous deletion of Lrg5 in mice resulted in neonatal lethality (12) . To investigate the role of Lgr5 in the lungs, Lgr5 +/-mice were used in the present study. The mice were housed in an individual ventilated cage (IVC) environment at 24±2˚C and 60±5% humidity with 12 h light/dark cycles. The mice were fed a bacteria-free diet. All mice were sacrificed under diethyl ether anesthesia. Guangdong Histology. The paraffin embedded tissues were sectioned at a thickness of 3-5 µm, and hematoxylin and eosin (H&E) staining was performed, as previously described (13) . Briefly, IHC was performed as follows: Antigen retrieval with ethylenediaminetetraacetic acid solution (pH 9.0), incubation of the slides in 3% H 2 O 2 at room temperature for 12 min, followed by washes and the blocking of non-specific proteins. The antibody was applied to the slides, which were subsequently incubated at 4˚C overnight. The tissue sections were washed again and the secondary antibody was applied to the slides. Finally, diaminobenzidine was used to visualize the positive staining on the slides. The primary Lgr5 antibody was used at a dilution of 1:100 (cat. no. sc-135238; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). The anti-rabbit secondary antibody was conjugated to horseradish peroxidase and was used at a dilution of 1:500 (cat. no. GK500705). The diaminobenzidine chromogen system was purchased from Gene Tech Co., Ltd.
(Shanghai, China). The slides were viewed on a BX51 Olympus microscope (Olympus Corporation, Shibuya, Japan).
Statistical analysis. All statistical analyses were performed using GraphPad Prism software version 5 (Graphpad Software, CA, USA). The χ 2 test or Fisher's exact test was used to analyze the association of Lgr5 expression with the clinicopathological parameters of the patients. The survival curves were plotted according to the Kaplan-Meier method to evaluate the Lgr5 expression levels with respect to the survival rate. The multivariate survival analyses were performed by a Cox proportional hazard model using the Wald test. P<0.05 was considered to indicate a statistically significant difference..
Results

Lgr5-positive cells are present in mouse lung tissue.
Lgr5 is well-characterized as a marker of normal stem cells in the intestine and as a marker of cancer stem cells. The Lgr5 homozygous knockout in mice resulted in neonatal lethality (12) . The present study suggested that Lgr5 serves an important role in development. However, the role of Lgr5-positive cells in the lung remains unknown. To investigate whether cells in normal mouse lung express Lgr5, normal lung tissue was obtained from C57/BL WT mice and the expression of Lgr5 was determined by IHC using a specific antibody. To confirm that the antibody was specific, normal mouse intestine was stained. The results are shown in Fig. 1A . In the lung tissue, the results demonstrated that some Lgr5-positive cells were present in the bronchi and alveoli (Fig. 1B and C) . The present study next determined whether the knockout of Lgr5 affected lung structure and found that the structure of the lung tissue of Lgr5 heterozygous knockout mice (Lgr5 +/-mice) differed from that of the WT mice. This finding indicated that the lung septa of Lgr5 +/-mice were thicker and that the lung structure was irregular compared with the WT mice (Fig. 1E) .
Lgr5 is expressed in lung adenocarcinoma, but not in squamous carcinoma. Based on the above IHC and histology results, the present study hypothesized that Lgr5 may serve a function in the maintenance of the morphology of bronchi or alveoli in the normal lung. It must be considered that lung tumor initiating cells are partly derived from the bronchi and that Lgr5 is a well-known marker of intestinal cancer stem cells. Therefore, in lung cancer, the present study assumed that Lgr5 is associated with tumor formation or to the tumor, node, metastasis (TNM) stage. Next, 122 lung cancer cases, including 102 cases of adenocarcinoma and 20 cases of squamous carcinoma, were subjected to IHC. The results showed that Lgr5 is not expressed in squamous cell carcinoma (0/20; P<0.001; Table I ; Fig. 2A) , however, is expressed in adenocarcinoma (47/122). The representative image of the staining is presented in Fig. 2B and C. Notably, in certain cases, Lgr5-positive cells were present in areas of tumor necrosis (Fig. 2D) , areas adjacent to the tumor (Fig. 2E) , and the lymphatic spaces and vascular lumina (Fig. 2F) .
Survival analysis of patients with lung adenocarcinoma as a function of Lgr5 expression.
The above data showed that Lgr5 is expressed in lung adenocarcinoma, but not in squamous carcinoma. Furthermore, the present study stained one tissue microarray that included 60 cases of lung adenocarcinoma to assess its expression by IHC using an Lgr5 antibody. These cases were classified into two groups as either '+' or '-', as shown in the representative image in Fig. 3A . The positive group was indicated by '+' and the negative group was indicated by '-'.
A survival analysis was performed for all patients with lung adenocarcinoma (paraffin blocks, 22 cases; TMA, 80 cases) using the Kaplan-Meier method. The follow-up periods ranged between 4 and 157 months. To evaluate the association between Lgr5 expression in lung adenocarcinoma cells and the clinicopathological parameters, the data from the patients was summarized in Table I . Lgr5 expression was not associated with tumor size (P= 0.075). In addition, no significant association was observed between Lgr5 expression and age, gender, tumor invasion or lymph node metastasis. However, Lgr5 expression was associated with TNM stage (P=0.026).
Additionally, the median survival was 30.5 months for patients in the Lgr5-negative group (n=55) and 12 months (n=47) for patients in the Lgr5-positive group, which indicated a significantly poorer survival rate of the Lgr5-positive group compared with the Lgr5-negative group (P=0.033). Next, univariable and multivariable analyses were performed to assess the effect of Lgr5 expression on survival. A Cox proportional hazards regression model was subsequently applied and the effect of Lgr5 on survival was estimated. The crude hazard ratio (HR) of the Lgr5-positive tumors compared with the Lgr5-negative tumors was 1.618 [95% confidence interval (CI), 1.06-2.48; P=0.027]. To estimate the independent pro-diagnostic effect of Lgr5 on survival, the present study adjusted for confounding factors. The present study involved 59 lung adenocarcinoma patients with lung cancer-associated mortalities and 5 variables that were included in the multivariate regression model. To determine whether Lgr5 expression was a single variable and not a potential confounding factor, a propensity score was applied. The five variables were clinicopathological factors, including age, tumor size, TNM stage, tumor invasion and metastasis. The adjusted HR of the Lgr5-positive group was 0.396 (95% CI, -0.28-1.06; P=0.15) compared with the Lgr5-negative group, which suggested that Lgr5 expression is not an independent risk factor for poorer survival (Table II) .
Discussion
Lgr5 is regarded as a marker of intestinal stem cells, which has attracted a significant amount of attention to this protein (8, (14) (15) (16) (17) (18) (19) . However, its role in the lungs and in lung cancer remains unclear (10) . The present study demonstrated Table I . Correlation between Lgr5 expression and the clinical and pathological characteristics of 122 cases of primary non-small cell lung cancer. Partial data are not available and all statistics were based on the informative data. for the first time, to the best of our knowledge, that the lungs of Lgr5 heterozygous mice exhibited structural abnormalities. Specifically, the pulmonary interstitium was thickened according to H&E staining. Additionally, Lgr5-positive cells were found in the mouse lung, including the alveoli. In addition, a few cells expressing Lgr5 were also found in the basal layer of the bronchial tissue. The above results suggested that Lgr5 may serve a significant role in the lung bronchi and alveoli. However, a determination of the function of these positive cells requires further clarification.
Lgr5 expression (%) --------------------------------------------------------------------------
In both the human and mouse gut, Lgr5-positive cells located in the intestinal crypts protect Paneth cells and are regarded as tumor stem cells (18) . In the present study, it was revealed that certain cells in normal lung tissue express Lgr5. This finding led us to question whether Lgr5 serves a role in normal lung tissue or if it is associated with lung cancer. Certain lung cancer cells are derived from the lung bronchi; therefore, Lgr5 expression in lung tumor tissues from patients with lung cancer was examined. Notably, Lgr5 is only expressed in lung adenocarcinoma and its expression is associated with TNM stage; however, Lgr5 expression not an independent factor for survival. In another study, the Lgr5-positive rate in lung adenocarcinoma was ~1/10 (11). However, in the present study, the rate reached ~50%. However, as the reasons that underlie this difference are unknown, additional studies are required for clarification. Cox proportional hazards regression model. TNM, tumor node metastasis; Lgr5, Leucine-rich repeat-containing G-protein coupled receptor 5. In previous studies, researchers have demonstrated that Lgr5 expression is associated with colorectal tumorigenesis and even colorectal cancer recurrence (20) . Previous studies have also reported that Lgr5 expression is correlated with tumor invasion and metastasis (15, 21, 22) . However, in the present experiments, the data did not indicate this phenomenon in lung adenocarcinoma. This difference may be because Lgr5 serves different roles in lung tumors compared with intestinal tumors. Notably, the presence of Lgr5-positive cells in lymphatic vessels were observed. Therefore, more experiments are required to investigate whether Lgr5 expression is associated with tumor metastasis (Fig. 3C) .
--------------------------------------------------------------------------------
In conclusion, the present study provided novel insights into the role of Lgr5 in normal lung tissue and lung cancer. It will be conducive for us to learn the role and function of Lgr5 in lung cancer.
